Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/levodopa (Sinemet CR4) in Parkinson's disease

• Published in: Neurology Vol. 40; no. 1; p. 70
• Main Authors: Nelson, M V, Berchou, R C, LeWitt, P A, Kareti, D, Galloway, M P
• Format: Journal Article
• Language: English
• Published: United States 01.01.1990
• Subjects: Adult; Aged; Antiparkinson Agents - administration & dosage; Antiparkinson Agents - blood; Antiparkinson Agents - pharmacokinetics; Carbidopa - administration & dosage; Carbidopa - pharmacokinetics; Delayed-Action Preparations; Drug Combinations - administration & dosage; Drug Combinations - pharmacokinetics; Female; Humans; Levodopa - administration & dosage; Levodopa - pharmacokinetics; Linear Models; Male; Middle Aged; Models, Biological; Parkinson Disease - drug therapy
• ISSN: 0028-3878
• DOI: 10.1212/WNL.40.1.70

Eight parkinsonian patients participated in a pharmacokinetic pharmacodynamic study of sequential doses of controlled-release carbidopa (CD)/levodopa (LD) at 4-hour intervals, with serial blood samples obtained before and after each dose. Effect measurements obtained with each blood sample included tapping and walking speed as well as a global assessment of motor function. Analysis of the data by extended least squares regression for linear, Emax, and sigmoid Emax pharmacodynamic models revealed that linear relationships do not provide the best fit between LD plasma concentrations and clinical effects after controlled-release CD/LD. The data are fit best to models that are curvilinear in nature. LD plasma concentrations greater than 2.0 micrograms/ml resulted in sustained effects on walking and global scores while the greatest rate of change in walking and global scores occurred at 0.9 micrograms/ml. LD plasma concentrations fluctuating around 0.9 micrograms/ml may result in the "on/off" effects seen in Parkinson's disease.